drugset / Trial / NCT02303951

Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC

NCT02303951

Phase 2 Terminated 47 enrolled University Hospital Tuebingen
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the efficacy, safety and biologic effects of neo-adjuvant treatment with vemurafenib + cobimetinib + atezolizumab in patients with limited metastasis of melanoma in stage IIIC/IV melanoma.

Timeline

Start
2015-01-22
Primary completion
2020-05-14
Completion
2020-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 840 mg Intravenous
Subject Cobimetinib Small molecule 60 mg Oral
Subject Vemurafenib Small molecule 720 mg Oral

Indications